CSL Limited (OTC:CSLLY) and uniQure Inc (NASDAQ:QURE) announced the four-year results from the pivotal HOPE-B study ...

研究人员发现，血友病A患者的唾液中含有位于囊泡上的外源性张力酶复合体（extrinsic tenase ...

Novo Nordisk’s bispecific antibody Mim8 prevented bleeding events and caused no adverse safety events in the Phase III ...

Global biotechnology leader CSL Behring (ASX:CSL; USOTC: CSLLY (OTC:CSLLY)) announced the four-year results from the HOPE-B ...

Novo Nordisk has bolstered the case for its near-approval hemophilia A drug candidate Mim8, linking the prospect to ...

Growing advancements in haemophilia treatment underscore a significant shift toward targeted and long-lasting therapeutic ...

The recent announcement by the government to provide free medicines for hemophilia patients is a welcome step forward in ...

A recent study led by MedUni Vienna provides new insights into the mechanisms of coagulation in persons with hemophilia A, the most common form of hemophilia. The research team was able to show ...

Federal funding ensures that hemophilia treatment centers can properly care for those with bleeding disorders, columnist Jennifer Lynne says.

Gene therapy has been available since 2022 for hemophilia B and since 2023 for hemophilia A, yet some major medical institutions have barely treated any patients so far. What’s the holdup?

Financial writer discusses MGX's gene editing technology, cash runway, and lack of clinical data for potential future ...

Saliva activates coagulation in persons with hemophilia A. ScienceDaily. Retrieved February 7, 2025 from www.sciencedaily.com / releases / 2025 / 01 / 250114125253.htm Medical University of Vienna.